IN THE HIGH COURT FOR THE STATE OF TELANGANA AT HYDERABAD
Nagesh Bheemapaka, J
Vivimed Labs Limited – Appellant
Versus
Central Bureau of Investigation – Respondent
WRIT PETITION No. 1843 OF 2026
| Table of Content |
|---|
| 1. factual history of business operations and administrative classification of fraud. (Para 1) |
| 2. distinction between independent criminal investigation and administrative banking regulations. (Para 2) |
| 3. compliance with rbi master directions and legitimacy of bank-led fraud identification. (Para 3) |
| 4. petitioner's rebuttals regarding jurisdictional validity of coercive state measures. (Para 4) |
| 5. identification of the central legal issue concerning interim stay vs. statutory criminal investigation. (Para 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12) |
| 6. independent nature of criminal investigations regarding cognizable economic offences. (Para 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21) |
| 7. precedents confirm criminal law operates distinctly from administrative fraud classification. (Para 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42) |
O R D E R:
Petitioner No.1 is a pharmaceutical manufacturing company established in 1991 and is stated to have engaged in manufacture and supply of pharmaceutical products in both domestic and international markets for more than three decades. According to Petitioners, the company developed a global presence and maintained business relationships with several multinational pharmaceutical companies including GlaxoSmithKline (GSK), Pfizer, Novartis, Procter & Gamble (P&G) and Abbott. They assert that the company expanded across multiple verticals within the pharmaceutical sector and maintained a workforce of more than 1200 employees, including approximately 250 medical representatives spread across eight States.
1.1. It is stated, during the financial year 2013-14, Petitioner No.1 acquired a USFDA-approved manufacturing facility from Actavis for a consideration exceeding Rs.122 Crores and further invested approximately Rs.100 Crores towards expansion of manufacturing capacity and development of new molecules. It is their case that stabilization of operations and receipt of regulatory approvals took longer than anticipated, thereby resulting in accumulated losses. During the course of such expansion, Respondent No.3 bank extended credit facilities to Petitioner No.1 company for financing its business expansion plans and the loans availed by the company were partly repaid.
1.2. Thereafter, petitioner No. 1 undertook various measures to repay its liabilities by liquidating assets which, according to Petitioners, exceeded the value of its debts. It is specifically contended that the company repaid Rs. 600 Crores by selling businesses and assets and by diluting its shareholding in its offshore subsidiary. Notwithstanding the aforesaid repayments, Petitioners were unable to clear the remaining outstanding loans amounting to Rs. 180.68 Crores on account of accumulated losses which, according to them, were aggravated by the COVID-19 pandemic. It is further stated that the company experienced cash mismatch on account of funding extended to subsidiary companies by leveraging its balance sheet.
1.3. Petitioner No.1 company also made several attempts to restructure its debt by offering one time settlements to Respondent No. 3 bank on different occasions and under varying terms. However, the restructuring efforts did not materialize, ultimately resulting in the loan account being classified as Non-Performing Asset (NPA) with effect from 28.01.2021. Thereafter, Respondent No.3 bank issued a show cause notice dated 16.08.2023 calling upon petitioners to submit their explanation within fifteen days as to why the account of Petitioner No.1 company should not be categorized and reported as "Fraud" under the applicable Reserve Bank of India guidelines. It is stated that the show cause notice referred to alleged irregularities noticed during periodic monitoring and review of the loan account and alleged suspicious fraudulent activity.
1.4. Petitioners submitted detailed replies dated 08.09.2023 and 01.12.2023 responding to the allegations contained in the show cause
Login now and unlock free premium legal research
Login to SupremeToday AI and access free legal analysis, AI highlights, and smart tools.
Login
now!
India’s Legal research and Law Firm App, Download now!
Copyright © 2023 Vikas Info Solution Pvt Ltd. All Rights Reserved.